Linker Architecture-Guided Design of FAPI Dimers for Improved Pharmacokinetics and FAP-Targeted Theranostics
Abstract Fibroblast activation protein (FAP), a type II transmembrane serine protease highly expressed in cancer-associated fibroblasts (CAFs), represents an attractive target for tumor imaging and targeted therapy. In this study, we designed and synthesized a series of FAP-targeted dimers (FAPI-FUSCC-DIMER) based on the UAMC1110 scaffold incorporating structurally diverse linkers and evaluated these compounds using a stepwise screening strategy to identify a promising FAP-targeted theranostic radioligand candidate. All FAPI-FUSCC-DIMER derivatives were efficiently labeled with 68Ga and exhibited favorable radiochemical stability and hydrophilic properties. Selected compounds were further evaluated in vivo based on SPR affinity assays and cell uptake studies. Micro-PET/CT imaging and biodistribution studies further evaluated the tumor uptake and retention profiles of the FAPI-FUSCC-DIMER series. FAPI-FUSCC-DIMER-2 demonstrated high FAP affinity, enhanced tumor uptake and prolonged tumor retention, with favorable pharmacokinetic properties, and was subsequently selected for 177Lu-based radioligand therapy studies. [177Lu]Lu-FAPI-FUSCC-DIMER-2 exhibited prolonged tumor retention for up to 120 h and a strong inhibitory effect on tumor growth in the HT-1080-FAP tumor model, together with a favorable safety profile. These findings support continued preclinical investigation of FAPI-FUSCC-DIMER-2.
Authors
- Fengsheng Zhang
- 许小平 (ORCID: https://orcid.org/0000-0002-8934-1287)
- Shaoli Song (ORCID: https://orcid.org/0000-0003-2544-7522)
- Meng Xiao
- Liyan Bai (ORCID: https://orcid.org/0009-0002-1964-2559)
- Xin Lu
- Jianping Zhang
- Dianjun Chen
- Chuan Huang
- Yao Wang (ORCID: https://orcid.org/0009-0000-1134-7833)
- Peng Liu
- Chao Wang
Institutions
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- Molecular Pharmaceutics
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1021/acs.molpharmaceut.6c01269
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China